Ark Invest co-founder and CEO Cathie Wood is one of the best-known growth investors in the realm of exchange-traded funds (ETFs). She also happens to be one of the most aggressive, loading up Ark Invest with high-flying and disruptive investments.

Cathie Wood stocks have done well in the past few months, with the ARK Innovation ETF (ARKK) soaring by 72% to $64. It has risen by 40% in the last 12 months compared to the Nasdaq 100 index that has risen by 24%.

In this article, we will take a look at 15 stocks in Cathie Wood’s stock portfolio. Cathie Wood is one of Wall Street’s most contentious figures. She founded ARK Investment Management around ten years ago and has over three decades of experience in the financial sector,

Cathie Wood and Ark Invest sold roughly $7,379,804 worth of Palantir stock — and spent $9,145,824 on three biotech stocks.

We'll get a fresh look at SoFi's latest results when it reports its 2024 year-end earnings on Monday, Jan. 27. But in the third quarter, SoFi's membership base grew by 756,000, its highest one-quarter new member additions ever.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing technology, using its patented gene sequencing platform to produce precise cures for diseases that need DNA tampering. CASGEVY, the company’s flagship medication developed in collaboration with Vertex Pharmaceuticals, was one of the first gene-edited treatments on the market.

Cathie Wood, head of ARK Investment Management, usually targets tech stocks that she says have a disruptive impact, even if the company is not profitable yet. Canada is a primary focus of Trump's tariff talks. The reasons why are varied. She is buying more shares of one of her favorite artificial intelligence positions.

Cathie Wood kept buying uranium refiner Cameco on Monday even as the DeepSeek reaction hammered nuclear-related stocks.